A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection
Latest Information Update: 24 Jan 2023
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ledipasvir; Sofosbuvir
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms APOSTLE
- 01 Jan 2023 Results published in the Journal of Medical Virology
- 02 Aug 2021 Status changed from active, no longer recruiting to completed.
- 16 Oct 2020 Planned End Date changed from 1 Feb 2021 to 1 Apr 2021.